AI
KLRS

Acuitas Investments’s Kalaris Therapeutics KLRS Stock Holding History

Acuitas Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-46,509
Closed -$865K – 122
2024
Q3 		$865K Buy
46,509
+3,690
+9% +$64.5K 0.39% 86
2024
Q2 		$712K Buy
42,819
+228
+0.5% +$4.03K 0.38% 82
2024
Q1 		$740K Buy
+42,591
New +$695K 0.37% 79

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acuitas Investments's KLRS Position: Q4 2024 in Review

Acuitas Investments sold out of Kalaris Therapeutics (KLRS) in Q4 2024, closing a stake of 46,509 shares — an estimated $865K sold.

Acuitas Investments first reported a position in KLRS in Q1 2024 and held it in 3 quarters. The position peaked at $865K in Q3 2024. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • Acuitas Investments reported no remaining Kalaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acuitas Investments sold 46,509 Kalaris Therapeutics shares in Q4 2024, an estimated $865K.
  • Acuitas Investments first reported a position in Kalaris Therapeutics in Q1 2024 and held it in 3 quarters.
  • Acuitas Investments's Kalaris Therapeutics position peaked at $865K in Q3 2024.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on Acuitas Investments's 13F filing for Q4 2024, filed 31 Jan 2025.